<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:com="http://www.sec.gov/edgar/common">
  <schemaVersion>X0202</schemaVersion>
<headerData>
    <submissionType>SCHEDULE 13D/A</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: Matrix Capital Management Company, LP -->
          <cik>0001410830</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>4</amendmentNo>
      <securitiesClassTitle>Common Stock, par value $0.00001 per share</securitiesClassTitle>
      <dateOfEvent>05/07/2026</dateOfEvent>
      <previouslyFiledFlag>false</previouslyFiledFlag>
      <issuerInfo>
        <issuerCIK>0001501796</issuerCIK>
        <issuerCusips>
          <issuerCusipNumber>05153U107</issuerCusipNumber>
        </issuerCusips>
        <issuerName>Aura Biosciences, Inc.</issuerName>
        <address>
          <com:street1>80 GUEST STREET</com:street1>
          <com:city>BOSTON</com:city>
          <com:stateOrCountry>MA</com:stateOrCountry>
          <com:zipCode>02135</com:zipCode>
        </address>
      </issuerInfo>
      <authorizedPersons>
        <notificationInfo>
          <personName>Joseph Downing</personName>
          <personPhoneNum>603-956-9145</personPhoneNum>
          <personAddress>
            <com:street1>Matrix Capital Management Company LP</com:street1>
            <com:street2>3 Pleasant Street, Suite 400</com:street2>
            <com:city>Portsmouth</com:city>
            <com:stateOrCountry>NH</com:stateOrCountry>
            <com:zipCode>03801</com:zipCode>
          </personAddress>
        </notificationInfo>
        <notificationInfo>
          <personName>Christopher Van Buren</personName>
          <personPhoneNum>(212) 373-3000</personPhoneNum>
          <personAddress>
            <com:street1>Paul, Weiss, Rifkind, Wharton &amp; Garrison</com:street1>
            <com:street2>1285 Avenue of the Americas</com:street2>
            <com:city>New York</com:city>
            <com:stateOrCountry>NY</com:stateOrCountry>
            <com:zipCode>10019</com:zipCode>
          </personAddress>
        </notificationInfo>
      </authorizedPersons>
    </coverPageHeader>
    <reportingPersons>
      <reportingPersonInfo>
        <reportingPersonCIK>0001410830</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Matrix Capital Management Company LP</reportingPersonName>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>DE</citizenshipOrOrganization>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
        <aggregateAmountOwned>0.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>0</percentOfClass>
        <typeOfReportingPerson>IA</typeOfReportingPerson>
        <typeOfReportingPerson>PN</typeOfReportingPerson>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonNoCIK>Y</reportingPersonNoCIK>
        <reportingPersonName>David E. Goel</reportingPersonName>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>X1</citizenshipOrOrganization>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
        <aggregateAmountOwned>0.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>0</percentOfClass>
        <typeOfReportingPerson>IN</typeOfReportingPerson>
        <typeOfReportingPerson>HC</typeOfReportingPerson>
      </reportingPersonInfo>
    </reportingPersons>
    <items1To7>
      <item1>
        <securityTitle>Common Stock, par value $0.00001 per share</securityTitle>
        <issuerName>Aura Biosciences, Inc.</issuerName>
        <issuerPrincipalAddress>
          <com:street1>80 GUEST STREET</com:street1>
          <com:city>BOSTON</com:city>
          <com:stateOrCountry>MA</com:stateOrCountry>
          <com:zipCode>02135</com:zipCode>
        </issuerPrincipalAddress>
        <commentText>The following constitutes Amendment No. 4 ("Amendment No. 4") to the Schedule 13D filed by the undersigned on November 4, 2021 (the "Original Schedule 13D"), as amended by Amendment No. 1 filed by the undersigned with the Securities and Exchange Commission (the "SEC") on December 7, 2022 ("Amendment No. 1"), Amendment No. 2 filed by the undersigned with the SEC on November 9, 2023 ("Amendment No. 2"), and Amendment No. 3 filed by the undersigned with the Securities and Exchange Commission on May 19, 2025 ("Amendment No. 3" and the Original Schedule 13D as amended by Amendment No. 1, Amendment No. 2, Amendment No. 3 and this Amendment No. 4, the "Schedule 13D"). This Amendment No. 4 amends and restates Item 5. Capitalized terms used herein and not otherwise defined in this Amendment No. 4 have the meanings set forth in the Schedule 13D. This Amendment No. 4 is the final amendment to the Schedule 13D and constitutes an "exit filing" for the Reporting Persons.</commentText>
      </item1>
      <item5>
        <percentageOfClassSecurities>See rows (11) and (13) of the cover pages to this Schedule 13D for the aggregate number of shares of Common Stock and percentages of the shares of Common Stock beneficially owned by each Reporting Person.</percentageOfClassSecurities>
        <numberOfShares>See rows (7) through (10) of the cover pages to this Schedule 13D for the number of shares of Common Stock as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.</numberOfShares>
        <transactionDesc>On April 30, 2026, the Matrix Fund agreed to sell and the Issuer agreed to repurchase 6,922,870 shares of Common Stock from the Matrix Fund at a price of $5.64 per share, contingent upon the closing of a separate equity offering by the Issuer and certain other conditions (the "Repurchase"). The Repurchase closed on May 7, 2026. Except for the Repurchase, no transactions in the shares of Common Stock have been effected by the Reporting Persons during the past sixty (60) days.</transactionDesc>
        <listOfShareholders>Not applicable</listOfShareholders>
        <date5PercentOwnership>May 7, 2026</date5PercentOwnership>
      </item5>
    </items1To7>
    <signatureInfo>
      <signaturePerson>
        <signatureReportingPerson>Matrix Capital Management Company LP</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ David E. Goel</signature>
          <title>David E. Goel, Managing General Partner</title>
          <date>05/11/2026</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>David E. Goel</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ David E. Goel</signature>
          <title>David E. Goel, Individually</title>
          <date>05/11/2026</date>
        </signatureDetails>
      </signaturePerson>
    </signatureInfo>
  </formData>
</edgarSubmission>
